{
    "Trade/Device Name(s)": [
        "TBI",
        "Glial fibrillary acidic protein (GFAP)",
        "Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1)"
    ],
    "Submitter Information": "Abbott Laboratories",
    "510(k) Number": "K232669",
    "Predicate Device Reference 510(k) Number(s)": [
        "K223602"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QAT"
    ],
    "Summary Letter Date": "September 29, 2023",
    "Summary Letter Received Date": "September 1, 2023",
    "Submission Date": "August 31, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.5830"
    ],
    "Regulation Name(s)": [
        "Brain trauma assessment test"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "misc"
    ],
    "Analyte(s)": [
        "Glial fibrillary acidic protein (GFAP)",
        "Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1)"
    ],
    "Specimen Type(s)": [
        "Plasma",
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT i1000SR System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent microparticle immunoassay (CMIA)",
        "Immunoassay"
    ],
    "Methodologies": [
        "Automated two-step immunoassay"
    ],
    "Submission Type(s)": [
        "Panel",
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott TBI panel using CMIA for measurement of GFAP and UCH-L1 on ARCHITECT i1000SR System to assist in brain trauma assessment.",
    "Indications for Use Summary": "Aids in evaluation of patients 18+ with suspected mild traumatic brain injury within 12 hours, assisting in determining need for head CT scan by measuring GFAP and UCH-L1 in plasma and serum; negative result is associated with absence of acute intracranial lesions on CT.",
    "fda_folder": "Immunology"
}